Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: FujiFilm, Hisun Team To Develop Flu Drug For Chinese Market

Executive Summary

Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.

You may also be interested in...



Finance Watch: VCs Are Sharing The Wealth With More Biopharmas

Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.

Asajes Offers Up Innovative Partnering Model For Asia Development

Asajes Ventures sees itself as offering a unique new mixed business model of venture capital and local development activity for smaller Western companies looking to develop their product or pipeline assets in Japan and China, aided by new opportunities from a rapidly reforming regulatory environment.

Takeda Offers Shire Asset Disposal To Assuage EC Merger Concerns

Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing. 

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel